Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin and Venetoclax in BTK-Resistant/Intolerant CLL/SLL
NCT03884972Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trabectedin in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose and schedule of trabectedin in combination with venetoclax. Planned start Jun 2019; status: withdrawn.
02
Drugs
trabectedin
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03884972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884972.